Precision HealthAI, a Manhattan startup whose artificial intelligence platform analyzes oncology data, has entered a licensing agreement with the American Society of Clinical Oncology’s CancerLinQ. The deal gives it access to more than 1 million cancer patient records.
Patient records are often lengthy and include multiple data types, such as faxes, scans and detailed notes on imaging, said Brigham Hyde, chief executive of Precision HealthAI. The startup will curate the data to enhance its usefulness for nonprofits, providers, researchers and government agencies.
With its AI platform, the company can also help fill in missing information about the stage of a patient’s cancer based on other clinical data.
“We can answer very specific questions that come up just for oncology,” Hyde said. “At the core of these questions is what treatments fit best to improve the outcomes of what patients.”
Precision HealthAI, as well as Chicago-based startup Tempus, will pay ASCO for access to the data. Hyde declined to disclose the terms of the licensing agreement.
The companies will be able to commercialize their findings from the data, which may have applications in drug discovery and designing clinical trials. The data come from 2,000 medical oncologists at community practices in 40 states and the District of Columbia.
Founded in 2016, Precision HealthAI raised $20 million in September in an investment round led by Palo Alto, Calif.–based SymphonyAI Group.